For those tracking functional foods with genuine microbiome impact, mulberry deserves more attention than it typically receives. While berries and fermented foods dominate gut-health conversations, this comprehensive review highlights how both mulberry leaves and fruits — through chemically distinct pathways — can meaningfully alter gut microbial architecture, with implications for metabolic health that go beyond simple prebiotic effects.
The review, published in Biomolecules, maps the phytochemical differences between mulberry plant parts: leaves are notably rich in 1-deoxynojirimycin (DNJ), a potent iminosugar that inhibits intestinal alpha-glucosidases, alongside flavonols and polysaccharides, while Morus nigra fruit contributes dense anthocyanin profiles with distinct bioactivity. Critically, the analysis underscores that processing variables — including drying temperature, fermentation, maceration duration, and extraction solvent polarity (aqueous versus hydroalcoholic) — substantially alter the bioactive compound profile and downstream bioavailability. These processing-driven shifts directly modulate how mulberry preparations interact with gut microbial communities. In preclinical models of metabolic dysfunction, mulberry-derived preparations were associated with enrichment of Bifidobacterium, Lactobacillus, and Akkermansia, alongside normalization of dysbiotic patterns and increased short-chain fatty acid output — notably acetate, propionate, and butyrate.
This review adds important nuance to the functional food literature by foregrounding processing methodology as a primary variable, not an afterthought. Most consumer-facing discourse treats 'mulberry extract' as a monolithic entity, yet this analysis reveals that an aqueous leaf extract and a hydroalcoholic fruit fraction may deliver substantially different bioactive loads and microbial responses. The dominant limitation here is the preclinical nature of most cited evidence — mouse and in vitro models are the primary substrate, and translating microbial shifts in rodents to clinically meaningful human outcomes remains a persistent challenge. DNJ's alpha-glucosidase inhibitory activity does have early human data supporting glycemic modulation, lending some translational credibility. Overall, this is a methodologically rigorous review that is confirmatory for experienced researchers but potentially paradigm-clarifying for clinicians and product developers who conflate mulberry preparations without accounting for sourcing and manufacturing variables.
